For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Intensity Therapeutics Inc (NASDAQ: INTS) closed the day trading at $0.42 down -9.74% from the previous closing price of $0.47. In other words, the price has decreased by -$9.74 from its previous closing price. On the day, 2.05 million shares were traded. INTS stock price reached its highest trading level at $0.46 during the session, while it also had its lowest trading level at $0.41.
Ratios:
For a better understanding of INTS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 3.60. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INTS now has a Market Capitalization of 25479558 and an Enterprise Value of 18530558.
Stock Price History:
The Beta on a monthly basis for INTS is 4.12, which has changed by -0.765 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, INTS has reached a high of $3.17, while it has fallen to a 52-week low of $0.19. The 50-Day Moving Average of the stock is 2.60%, while the 200-Day Moving Average is calculated to be -37.63%.
Shares Statistics:
Over the past 3-months, INTS traded about 30.39M shares per day on average, while over the past 10 days, INTS traded about 4980600 shares per day. A total of 60.06M shares are outstanding, with a floating share count of 54.81M. Insiders hold about 8.76% of the company’s shares, while institutions hold 4.93% stake in the company. Shares short for INTS as of 1764288000 were 2507610 with a Short Ratio of 0.08, compared to 1761868800 on 16769283. Therefore, it implies a Short% of Shares Outstanding of 2507610 and a Short% of Float of 4.33.
Earnings Estimates
A comprehensive evaluation of Intensity Therapeutics Inc (INTS) is underway, with the input of 3.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.06 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.32 and -$0.37 for the fiscal current year, implying an average EPS of -$0.34. EPS for the following year is -$0.22, with 2.0 analysts recommending between -$0.19 and -$0.25.
